Key Highlights
- The pharmaceutical giant is reportedly negotiating a deal exceeding $2 billion to purchase Kelonia Therapeutics, according to WSJ sources
- An official announcement may come as soon as Monday, with additional performance-based payments potentially included
- Kelonia specializes in innovative CAR-T cell therapy targeting multiple myeloma, a type of blood cancer
- The Massachusetts-based startup has secured approximately $60 million in funding and carried a valuation slightly above $100 million in 2022
- This acquisition would strengthen Lilly’s cancer treatment portfolio while diversifying beyond its highly successful obesity medications
According to sources cited in a Wall Street Journal article released Sunday, Eli Lilly has entered late-stage negotiations to purchase Kelonia Therapeutics, a Boston-based biotech company, for a sum exceeding $2 billion. While an announcement could potentially come as early as Monday, sources indicate that discussions remain ongoing and could still collapse.
The WSJ report noted that the financial arrangement may feature performance-based milestone payments in addition to the base acquisition price, according to individuals with knowledge of the negotiations.
Shares of LLY stock gained approximately 2.55% following the news.
Kelonia operates as a clinical-stage biotechnology firm specializing in CAR-T cellular therapies — innovative treatments that engineer a patient’s immune cells to identify and eliminate cancerous cells.
The company’s primary research centers on multiple myeloma, a malignancy affecting blood plasma cells. Kelonia’s proprietary methodology seeks to streamline CAR-T procedures by eliminating the requirement for chemotherapy pretreatment and reducing the complicated cellular manufacturing processes normally associated with such therapies.
This represents a significant advancement in the CAR-T field, where operational complexity has historically created substantial barriers to widespread adoption.
Kelonia’s total fundraising to date amounts to slightly less than $60 million. The company’s most recent valuation stood at approximately $100 million in 2022 — making the reported acquisition price of over $2 billion a substantial premium.
Eli Lilly and Kelonia did not respond to Reuters’ requests for comment outside regular business hours.
Strengthening the Oncology Pipeline
Lilly maintains an existing presence in the cancer treatment market. The company’s current oncology portfolio features Jaypirca and the breast cancer medication Verzenio, alongside several experimental candidates in development.
Acquiring Kelonia would significantly enhance Lilly’s position in hematologic malignancies, a rapidly expanding oncology subsector.
This transaction aligns with established trends in Lilly’s M&A activity. The company has pursued aggressive acquisition strategies, supported by substantial revenue from its blockbuster obesity drug Zepbound and the diabetes medication Mounjaro.
Earlier this year in February, Lilly announced plans to purchase Orna Therapeutics in a transaction valued at up to $2.4 billion. The Kelonia acquisition would represent another significant transaction within a compressed timeframe.
Strategic Diversification Beyond Weight-Loss Medications
Lilly has publicly communicated its commitment to portfolio diversification. The pharmaceutical company has systematically expanded into therapeutic areas including inflammatory bowel conditions, ophthalmic disorders, oncology, and gene-modification technologies through strategic acquisitions and collaborative partnerships.
CAR-T cellular therapies align precisely with this strategic direction. These treatments have demonstrated significant clinical success in hematologic cancers, with multiple therapies already receiving regulatory approval — though manufacturing complexity and treatment costs continue to pose industry-wide challenges.
Kelonia’s streamlined therapeutic approach represents its primary value proposition. If the company can demonstrate clinical efficacy while reducing logistical barriers, this represents a meaningful competitive advantage justifying premium acquisition pricing.
Lilly has not issued official confirmation of the transaction. The Wall Street Journal indicated that negotiations could still terminate before any formal announcement.
LLY stock was trading approximately 2.55% higher following publication of the report.
